Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment?
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
32471814
PubMed Central
PMC7536742
DOI
10.2215/cjn.15861219
PII: 01277230-202010000-00022
Knihovny.cz E-resources
- Keywords
- ANCA, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibodies, Antineutrophil Cytoplasmic, vasculitis,
- MeSH
- Azathioprine therapeutic use MeSH
- Cyclophosphamide therapeutic use MeSH
- Granulomatosis with Polyangiitis complications drug therapy MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Humans MeSH
- Microscopic Polyangiitis complications drug therapy MeSH
- Myeloblastin immunology MeSH
- Kidney Diseases etiology physiopathology MeSH
- Peroxidase immunology MeSH
- Antibodies, Antineutrophil Cytoplasmic * MeSH
- Recurrence MeSH
- Rituximab therapeutic use MeSH
- Maintenance Chemotherapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Azathioprine MeSH
- Cyclophosphamide MeSH
- Immunosuppressive Agents MeSH
- MPO protein, human MeSH Browser
- Myeloblastin MeSH
- Peroxidase MeSH
- Antibodies, Antineutrophil Cytoplasmic * MeSH
- Rituximab MeSH
See more in PubMed
Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ: Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64: 3452–3462, 2012. PubMed PMC
Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D; European Vasculitis Study Group : Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64: 542–548, 2012. PubMed
Walsh M, Faurschou M, Berden A, Flossmann O, Bajema I, Hoglund P, Smith R, Szpirt W, Westman K, Pusey CD, Jayne DR; European Vasculitis Study Group : Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 9: 1571–1576, 2014. PubMed PMC
Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D; EUVAS investigators : Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955–960, 2012. PubMed
Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, Segelmark M, Guillevin L, Jayne D; European Vasculitis Society : Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76: 1662–1668, 2017. PubMed
de Joode AAE, Sanders JSF, Puéchal X, Guillevin LP, Hiemstra TF, Flossmann O, Rasmussen N, Westman K, Jayne DR, Stegeman CA: Long term azathioprine maintenance therapy in ANCA-associated vasculitis: Combined results of long-term follow-up data. Rheumatology (Oxford) 56: 1894–1901, 2017. PubMed
Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U; RAVE-ITN Research Group : Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75: 1166–1169, 2016. PubMed PMC
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group : Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 65: 2441–2449, 2013. PubMed PMC
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L; French Vasculitis Study Group : Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 1771–1780, 2014. PubMed
Mahr A, Specks U, Jayne D: Subclassifying ANCA-associated vasculitis: A unifying view of disease spectrum. Rheumatology (Oxford) 58: 1707–1709, 2019. PubMed
